Search clinical trials for: GMI-1359

Total 1638 results

GlycoMimetics Incorporated

Terminated

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Breast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast Cancer

United States
GlycoMimetics Incorporated
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Healthy

United States
Niiki Pharma Inc.

Completed

Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors

Solid Tumors

United States
Talima Therapeutics, Inc.

Terminated

A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis

Distal Subungual Onychomycosis

United States
Takeda

Completed

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

Norovirus

Finland, Panama, Colombia
University of Pittsburgh
National Institute of Mental Health (NIMH); Kaiser Foundation Research Institute

Withdrawn

Bridging the Gap to Improve Mental Health Treatment Utilization

Depression | Anxiety | Suicidal Ideation | Adolescent Behavior

United States
GlycoMimetics Incorporated

Completed

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Sickle Cell Disease

United States
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
GlycoMimetics Incorporated

Completed

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

Healthy Adult Subjects

United States
University of Minnesota
National Institute of Nursing Research (NINR); National Institutes of Health...

Completed

Intervention to Improve Expression of End of Life Preferences for Homeless Persons (SELPH)

Healthy

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Healthy | Renal Impairment

United States
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Norwalk Gastroenteritis | Norovirus Infections

China
GlycoMimetics Incorporated

Terminated

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia | Vaso-occlusive Crisis | Pain Crisis | Sickle Cell Disorders

United States, Canada
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Healthy

United States
Shandong Suncadia Medicine Co., Ltd.

Enrolling by invitation

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

Breast Cancer

China
St. Ambrose University

Completed

Graded Motor Imagery and Fall Risk in Older Adults (GMI)

Balance | Fall Risk

United States
University of Tromso
University Hospital of North Norway

Recruiting

A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks.

Complex Regional Pain Syndrome

Norway
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
GlycoMimetics Incorporated

Completed

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Sickle Cell Disease | Vaso-occlusive Crisis | Pain Crisis

United States, Canada
Artvin Coruh University
Marmara University

Active, not recruiting

The Effect of Graded Motor Imagery on Pain and Function in Individuals With Knee Osteoarthritis

Knee Osteoarthritis | Limitation, Mobility

Turkey
University of Illinois at Urbana-Champaign
University of Washington

Not yet recruiting

Peer MI in FQHCs for Substance-using Emerging Adults

Substance Use Disorders

United States
Ergoterapia Manoegomito Sagl

Unknown

EFFECTIVENESS OF GRADED MOTOR IMAGERY TO PREVENT CRPS IN PATIENTS WITH DISTAL RADIUS FRACTURE AFTER SURGERY

Surgery | Distal Radius Fracture | CRPS (Complex Regional Pain Syndromes) | Wrist Fracture
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Disc Medicine, Inc

Enrolling by invitation

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP

Erythropoietic Protoporphyria

United States, Australia
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Recruiting

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections

China
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
GlycoMimetics Incorporated

Completed

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Anemia, Sickle Cell

United States, Canada
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

Psoriasis

Australia, New Zealand
Mitsubishi Tanabe Pharma Corporation

Completed

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

Myocardial Infarction

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
Quintessence Biosciences, Inc.

Unknown

A Study of QBI-139 in Subjects With Advanced Solid Tumors

Solid Tumors

United States
GlycoMimetics Incorporated

Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Multiple Myeloma

Ireland, Denmark, United Kingdom, Germany
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Langerhans Cell Histiocytosis | LCH

China
Shanghai Fosun Pharmaceutical Industrial Development...

Suspended

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Melanoma

China
AstraZeneca

Completed

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Crohn's Disease

United States, Australia
Icon Genetics GmbH
University Hospital, Ghent

Completed

Recombinant, Bivalent, Norovirus Vaccine Study

Norovirus

Belgium
Takeda

Completed

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Healthy Participants | Norovirus

United States
Takeda

Completed

Bivalent Norovirus Vaccine Study

Gastroenteritis

United States
Takeda

Completed

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Congestive Heart Failure

United States
IRCCS San Camillo, Venezia, Italy

Unknown

Graded Motor Imagery for Patients Within a Year After Stroke. (GMI)

Stroke

Italy
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Vaxart

Active, not recruiting

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Norovirus Infections

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Mansoura University

Unknown

Effect of Gastric Balloon in Morbid Obesity: Prospective Study

Morbid Obesity

Egypt
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

Meningitis | Meningococcal Infections

United States

3

Subscribe